Gingival Hyperplasia Secondary to Everolimus Therapy

The document presents a case of a 34-year-old woman with type 1 diabetes who developed gingival hyperplasia, a condition characterized by the thickening of the gums, following the introduction of everolimus treatment for her kidney transplant. The patient also experienced erosive lesions on the oral mucosa and lips, as well as intense halitosis. The diagnosis of gingival hyperplasia was made based on the temporal relationship with the start of everolimus therapy. Despite the discomfort caused by the condition, discontinuation of everolimus was not considered due to its effectiveness in controlling the kidney transplant. The patient was advised to maintain rigorous oral hygiene and regular dental check-ups. The case is notable as the authors found no other reports of gingival hyperplasia secondary to everolimus in their literature review. Drug-induced gingival hyperplasia is generally reversible and can be managed by avoiding or substituting the causative drug and maintaining strict dental hygiene. Everolimus is a newer immunosuppressant with better bioavailability and a shorter half-life, used to prevent rejection of solid organ transplants, and is associated with various adverse reactions including skin issues, but gingival hyperplasia had not been previously reported.